Design of potent inhibitors for human brain memapsin 2 ([beta]-secretase).
Structure-based design: potent inhibition of human brain memapsin 2 ([beta]-secretase).
Patent and Trademark Office has issued a fundamental patent covering key tools for the discovery of memapsin 2 inhibitors for use in the treatment of Alzheimer's Disease.
Memapsin 2 (beta-secretase) has generated intense research interest as a target for drugs to treat Alzheimer's Disease, based on its early role in the chain of events that leads to amyloid plaque formation, the hallmark of the disease.
This patent, one of the first to issue in the Memapsin 2 area, underscores the leading position Zapaq has built in the discovery of inhibitors for this disease.
The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2
substrate that can inhibit the function of memapsin 2
Memapsin 2 works with another enzyme, gamma-secretase, to cut a longer protein called amyloid precursor protein.
The enzyme and inhibitor concept for Memapsin 2 is similar to the protease inhibitors created to fight HIV and AIDS.
Discovery of Memapsin 2
(BACE1), Design of Inhibitors and Drug-design Tools
Patent on Tools for Discovering Memapsin 2
(beta-secretase) Inhibitors DCTU019 04/15/2003 10:04 r f bc-VA-TRADOS-FBI-Contrct (ALEXANDRIA) FBI Deploys TRADOS Solutions to Cope With Increased Translation Volumes FLTU008 04/15/2003 10:04 r f bc-FL-Diamond-bikes (SUNRISE) Diamond Powersports Announces New Product Line for Motorcycle Aftermarket Leading To Increased Sales NYTU073 04/15/2003 10:05 r f bc-NY-Amex-lists-Arena (NEW YORK) American Stock Exchange Lists Stock of Arena Resources Inc.
Researchers at the Oklahoma Medical Research Foundation (OMRF) have successfully designed a highly potent inhibitor for Memapsin 2, the enzyme believed to be directly responsible for Alzheimer's disease.
identified and produced Memapsin 2 earlier this year.